Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy

Autor: Salles, GA, Catalano, J, Feugier, P, Offner, FC, Bouabdallah, R, Caballero, D, Brice, P, Pedersen, Lars Møller, Haioun, C, Belada, D, Delmer, A, Simpson, D, Tilly, H, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, Gomes de Silva, M, Sebban, C, Lister, A, Esrell, JA, Milone, G, Sonet, A, Lopez-Guillermo, A, Seymour, JF

Publikováno v: Salles, GA, Catalano, J, Feugier, P, Offner, FC, Bouabdallah, R, Caballero, D, Brice, P, Pedersen, L M, Haioun, C, Belada, D, Delmer, A, Simpson, D, Tilly, H, Leppa, S, Soubeyran, P, Hagenbeek, A, Casasnovas, O, Intragumtornchai, T, Fermé, C, Gomes de Silva, M, Sebban, C, Lister, A, Esrell, JA, Milone, G, Sonet, A, Lopez-Guillermo, A & Seymour, JF 2010, ' Updated results of the PRIMA study confirms the benefit of 2-years rituximab maintenance in follicular lymphoma patients responding to immunochemotheraphy ', Blood, vol. 116, pp. 746 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::1f68f1897d9e82d509c339afcf7bb01d
https://portal.findresearcher.sdu.dk/da/publications/a668486b-5213-47fc-a536-f34513e63a93